Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

benzinga.com/news/fda/25/06/45815227/pfizer-arvinas-partnered-breast-cancer-drug-cuts-progression-risk-by-43-in-trial-seeks-fda-approval

Arvinas, Inc. (NASDAQ:ARVN) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:PFE).
The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal…

This story appeared on benzinga.com, 2025-06-06 14:18:34.
The Entire Business World on a Single Page. Free to Use →